Tag Archives: opdivo

Relapsed Mesothelioma Patients Live Longer on Opdivo in Phase 3 Trial

relapsed mesothelioma patients

A multi-center British study suggests that the cancer drug Opdivo (nivolumab) may be a solid second-line treatment option for relapsed mesothelioma patients.  The Phase-3 trial involved mesothelioma patients from 24 UK hospitals. All had an ECOG score of 0 or 1, meaning they were in reasonably good health overall.  All of the patients had first-line treatment with platinum-based chemotherapy. Then their cancer came back. There is no approved treatment for relapsed mesothelioma patients. So these patients enrolled in the nivolumab trial.  Although Opdivo is not a cure for mesothelioma, the results of the news trial show it could extend survival for the right patients.  How Does Opdivo Work? Nivolumab is sold under the brand name Opdivo. It is an immunotherapy … Continue reading Relapsed Mesothelioma Patients Live Longer on Opdivo in Phase 3 Trial »

Yervoy and Opdivo for Mesothelioma: Three Year Results Still Look Good

Yervoy and Opdivo for mesothelioma

Three years after the last patients enrolled in the clinical trial of Yervoy and Opdivo for mesothelioma, survival results still look promising for this immunotherapy treatment.  Researchers presented an update of the CheckMate 743 trial at the recent virtual conference of the European Society for Medical Oncology (ESMO). The team found that more than 23% of patients on Yervoy and Opdivo for mesothelioma were still alive at three years. Only 15% of the chemotherapy group were still living.  Immunotherapy for Malignant Mesothelioma Alimta (pemetrexed) was the first drug to receive FDA approval for mesothelioma chemotherapy. The FDA approved it in 2004.  Before Alimta, patients had even fewer options that they do today. Most mesothelioma patients now start treatment with a … Continue reading Yervoy and Opdivo for Mesothelioma: Three Year Results Still Look Good »

Opdivo as Second-Line Treatment Option for Mesothelioma: Promising New Data

second-line treatment option

A new study suggests that the cancer drug Opdivo could be an effective second-line treatment option for people with relapsed mesothelioma. Right now, people whose mesothelioma comes back after treatment do not have an approved second-line treatment option.  The news on Opdivo comes from the first ever placebo-controlled phase 3 trial of patients with relapsed mesothelioma. It shows that the drug significantly improved overall survival for these patients. It also increased the time it took for patients’ cancer to get worse. Details of the CONFIRM Trial The trial of this proposed second-line treatment option for mesothelioma was called CONFIRM. It involved 332 mesothelioma patients from 24 UK cancer centers. The patients already had at least one treatment. Two thirds of … Continue reading Opdivo as Second-Line Treatment Option for Mesothelioma: Promising New Data »

Breakthroughs in Mesothelioma in 2020

breakthroughs in mesothelioma

In spite of a global pandemic, there were some major breakthroughs in mesothelioma in 2020 that made the year a hopeful one for people fighting asbestos cancer. Malignant mesothelioma is the most serious illness caused by exposure to asbestos fibers.  Mesothelioma is still not curable. But researchers have made major breakthroughs in mesothelioma diagnosis, prognosis, and treatment this year.  Mesothelioma Treatment Advances Mesothelioma treatment saw the biggest breakthroughs in mesothelioma in 2020. The FDA approved the first systemic treatment for mesothelioma since 2004. That was the year that Alimta (pemetrexed) received approval.  They approved a combination of the immunotherapy drugs Opdivo and Yervoy. Yervoy helps activate and proliferate T-cells. Opdivo helps existing T-cells discover the mesothelioma  tumor. The patients who … Continue reading Breakthroughs in Mesothelioma in 2020 »

Cholesterol Drugs Extend Mesothelioma Survival in New Study

cholesterol drugs

Cholesterol drugs called statins have been shown to improve survival among mesothelioma patients taking PD-1 inhibitors.  The news comes from an international study from cancer researchers in Italy and the Netherlands.  More than 250 patients with pleural mesothelioma or non-small cell lung cancer were evaluated for the study. Researchers found that those who took cholesterol drugs while also receiving PD-1 blockers like Keytruda lived longer and had slower disease progression.  Mesothelioma Patients and Statins The body needs some cholesterol to build healthy cells. But many adults have too much cholesterol in their blood. This can lead to fatty deposits in the arteries that raise the risk for heart disease and stroke.  Cholesterol drugs called statins are designed to bring cholesterol … Continue reading Cholesterol Drugs Extend Mesothelioma Survival in New Study »

T-Cells Test May Predict Success of New Drug Combination for Mesothelioma

new drug combination for mesothelioma

A month after the FDA approved a new drug combination for pleural mesothelioma, scientists are discovering more about who might benefit the most from this treatment.  A new report in EBioMedicine suggests that the success of the new drug combination for mesothelioma depends on the presence and activation of special immune system cells. Researchers in the Netherlands found that patients with enough of the right kind of T-cells had the best results. The findings could help doctors screen out mesothelioma patients who are less likely to benefit.  The Long-Awaited New Drug Combination for Mesothelioma  The two medicines in the new drug combination for mesothelioma are nivolumab (Opdivo) and ipilimumab (Yervoy).  The FDA approved a mix of the two immunotherapy drugs … Continue reading T-Cells Test May Predict Success of New Drug Combination for Mesothelioma »

New Drug Combination for Mesothelioma Wins FDA Approval

New Drug Combination for Mesothelioma

The FDA has approved a new drug combination for mesothelioma. It is the first systemic treatment for mesothelioma to win FDA approval in 16 years.  The combination includes a pair of immunotherapy drugs that complement each other. Both drugs are immune checkpoint inhibitors. They are approved to treat people with inoperable pleural mesothelioma.  “Today’s approval of nivolumab plus ipilimumab provides a new treatment that has demonstrated an improvement in overall survival for patients with malignant pleural mesothelioma,” says Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence. New Treatment Options Needed Pleural mesothelioma is a virulent cancer of the membrane that surrounds the lungs. Asbestos exposure is usually the trigger. Many countries have banned asbestos. In the US, … Continue reading New Drug Combination for Mesothelioma Wins FDA Approval »

“Exceptional Survival” in Some Patients on Nivolumab for Mesothelioma

nivolumab for mesothelioma

A real-world study of Dutch patients suggests that nivolumab for mesothelioma can dramatically extend survival in the right patients.  Nivolumab is sold under the brand name Opdivo. It is a type of immunotherapy. It works by making cancer cells more vulnerable to attack. The FDA approved nivolumab to treat non-small cell lung cancer and some other cancers.  It is still in the testing phase for malignant mesothelioma. The new report suggests that careful patient selection is the key to making nivolumab for mesothelioma work.  Why Nivolumab for Mesothelioma? Malignant mesothelioma is an aggressive cancer caused by past exposure to asbestos. Like other types of cancer, it has ways of protecting itself from immune system attack. A protein called PD-L1 is … Continue reading “Exceptional Survival” in Some Patients on Nivolumab for Mesothelioma »

Non-Epithelioid Mesothelioma: Immunotherapy Combo Could be the New Standard of Care

Two immunotherapy drugs could become the new standard of care for people with non-epithelioid mesothelioma.  All forms of malignant mesothelioma are deadly. But people with a non-epithelioid mesothelioma subtype are less likely to respond to standard treatments. Their variety of mesothelioma is especially resistant to chemotherapy with cisplatin and Alimta. This has been the mainstay of pleural mesothelioma treatment since 2004. But a new trial shows two immunotherapy drugs extended mesothelioma survival better than chemotherapy. This could be especially good news for patients with non-epithelioid mesothelioma.  Checkpoint Inhibitors for Mesothelioma Most people with pleural mesothelioma start with chemotherapy. Chemotherapy can often extend life by a few months. It is most beneficial for patients with epithelioid mesothelioma. But this approach does … Continue reading Non-Epithelioid Mesothelioma: Immunotherapy Combo Could be the New Standard of Care »

Opdivo for Mesothelioma Recurrence is Safe and Effective, Study Finds

Opdivo for mesothelioma recurrence

A new Japanese study appears to show that Opdivo for mesothelioma recurrence after surgery is safe and effective.  Opdivo (nivolumab) is an immunotherapy drug similar to Keytruda (pembrolizumab). It blocks a protein called PD-L1. PD-L1 helps mesothelioma cells avoid detection by the immune system.  In the latest study, 35 patients received Opdivo for mesothelioma recurrence. More than three quarters of them experienced either stable or decreased disease. Understanding How Nivolumab Works Nivolumab is most often used to treat non-small cell lung cancer. It makes tumors more vulnerable to immune system attack. Pleural mesothelioma has many of the same characteristics as lung cancer. This is one reason researchers are hopeful about Opdivo for mesothelioma recurrence.  The primary treatment for mesothelioma is … Continue reading Opdivo for Mesothelioma Recurrence is Safe and Effective, Study Finds »